124880-20-2

Basic information

• Product Name: 1-[(4-chlorobutyl)thiomethyl]-3,4-dichlorobenzene
• CAS NO: 124880-20-2
• Molecular Weight: 283.649
• Mol File: 124880-20-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 1-[(4-chlorobutyl)thiomethyl]-3,4-dichlorobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[(4-chlorobutyl)thiomethyl]-3,4-dichlorobenzene(124880-20-2)
• EPA Substance Registry System: 1-[(4-chlorobutyl)thiomethyl]-3,4-dichlorobenzene(124880-20-2)

Safety Data

• Hazardous Substances Data: 124880-20-2(Hazardous Substances Data)

Upstream product

• 102-47-6 3,4-Dichlorophenylmethyl chloride 
• 22297-13-8 S-(3,4-dichlorobenzyl)isothiourea 
• 6940-78-9 4-chlorobutyl bromide 
• 36480-40-7 3,4-dichlorobenzyl mercaptan 

Downstream Products

• 124880-22-4 3-cyano-1-[(4-chlorobutyl)thiomethyl]benzene 
• 124879-91-0 (1R,2R)-2-(3,4-Dichloro-phenyl)-1-oxo-hexahydro-1λ⁴-thiopyran-2-carbothioic acid methylamide 
• 124880-06-4 2-(3,4-Dichloro-phenyl)-tetrahydro-thiopyran 1-oxide 
• 124880-15-5 1,2-Dichloro-4-(4-chloro-butane-1-sulfinylmethyl)-benzene 

Relevant articles and documents

Synthesis and Biological Activity of trans-(+/-)-N-Methyl-2-(3-pirydyl)-2-tetrahydrothiopyrancarbothioamide 1-Oxide (RP 49356) and Analogues: A New Class of Potassium Channel Opener

The synthesis and biological activity of trans-(+/-)-N-methyl-2-(3-pyridyl)-2-tetrahydrothiopyrancarbothioamide 1-oxide (8a, RP 49356) and analoques is reported.These compounds constitute a new structural class of K+-channel opener.The effects of changes in the pyridyl group, thioamide, and thiane ring on in vitro K+-channel opening activity are discussed.A 3-pyridyl or 3-quinolyl group, a small N-alkyl thioamide function, and a thiane oxide ring, in which the sulfoxide is in a trans relationship to thioamide, are preferred for activity.Selected compounds were tested intravenously in the normotensive anaesthetized rat for hypotensive effects, and the activities reflect their in vitro K+-channel opening activity.This led to further evaluation of compound 8a and the selection of the (-)-enantiomer 8b (RP 52891) for development as an antihypertensive and antianginal agent.